Shrewsbury cancer charity ready for clinical trials of new drug
Decisions about which medicines are made available on the NHS are made by different organisations in England, Wales and Scotland.Decisions are usuaully based on factors, including the evidence available about a drug and the length by which it could extend patients' lives.Input from experts and public involvement is also considered.
Mr Crane said Valoxydin was an anti-metastatic drug which targeted the formation of secondary tumours – also known as metastases - in the body and stopped the primary cancer from spreading.Testing showed the drug could potentially reduce the spread of lung cancer by approximately 80% in animal models, he added.Fellow trustee Ted Youngman, whose father died with lung and brain cancer 15 years ago, said from the initial theory about how the treatment might work, they had begun to experiment with the drug in a petri dish and had gone through more than 50 variations to reach the point it was now at.
'Tremendous'
"There's a lot of work still to go, but this is tremendous," Mr Youngman said.He added: "It's much easier to stop [cancer] from spreading than it is to treat it once it's already spread."That's the approach we're taking, which we think is a bit different from other treatments before now."The charity's founders believe it might be possible the drug could be developed for use in the treatment of liver, kidney and bowel cancer, but added a significant amount of additional funding would be needed for further research.Conversations with potential large-scale backers had already begun, Mr Crane said.He said the process could take two to three years, at which point it might be ready for consideration by the NHS.The drug would be taken as a pill, which would mean it was relatively easy to administer to patients.Mr Crane said the drug would need to be taken daily for the rest of the patient's life – or until another solution is discovered.
Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
21 minutes ago
- BBC News
Newcastle University kidney drug research 'may be life-changing'
Early withdrawal of a treatment for people with a rare kidney disease is possible without relapse, safer for patients and saves the NHS millions of pounds, researchers Haemolytic Uraemic Syndrome (aHUS) is a life-threatening condition caused by an uncommon defect in the immune system which, in the past, led to kidney failure.A study by Newcastle University has found most patients can stop taking the drug eculizumab after six months and their disease will not return. Prof Neil Sheerin, who led the study, said the findings had "the potential to significantly change the way we manage aHUS and this may be life-changing for some patients". Ending the use of the drug after six months could lead to NHS savings of £4.2m per patient over their lifetime, the university chiefs previously recommended patients stay on eculizumab for the rest of their lives although that leads to an increased risk of meningococcal sepsis. 'I feel like myself again' Twenty-eight people, aged two to 59, from England and Scotland and who had been on eculizumab for at least six months, took part in the patients had their treatment withdrawn. Only four participants' kidney disease returned and the remaining 24 have remained aHus-free to date, the university those taking part was Louise Percival, of York, who was diagnosed with aHus in 35-year-old said she had suffered several side effects, such as migraines, hair loss and breathlessness, before being taken off eculizumab during the described the findings as fantastic."When I was diagnosed with aHUS I felt overwhelmed as it was a huge burden to live with," she said. "It was life-changing as it's something that will never go away."I strongly disliked the eculizumab infusions as they had to be given religiously every two weeks, which impacted my holidays and social events."I'm a very active person, enjoying hiking and the gym, so the side effects and time needed for the treatment were detrimental to my quality of life."I have a fear of needles, so having a cannula put in my arm every fortnight was very distressing."All of the side effects disappeared and I feel like myself again." Prof Sheerin said when a patient initially started treatment for aHUS "they faced a lifetime of eculizumab and the dangers associated with it"."Now we have shown that many people can stop the treatment, freeing them from the burden of regular intravenous injections and removing risk of serious infection associated with the drug," he said."In addition, significant efficiency savings for the NHS of £110.4m over five years could be realised in this patient population through more targeted use of this high-cost treatment."The study was funded by the National Institute for Health and Care Research and published in The Lancet Regional Health Europe. Follow BBC North East on X, Facebook, Nextdoor and Instagram.
The Sun
22 minutes ago
- The Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". 2 It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
The Independent
an hour ago
- The Independent
Yellow heat health alert issued across parts of the country
A yellow heat-health alert has been issued for parts of the UK, effective from 12pm on Monday, August 11 until 6pm on Wednesday, August 13. It covers Yorkshire and the Humber, East Midlands, East of England, London, the South East and South West. Temperatures are forecast to soar well above 30C, potentially reaching the mid-30s in southern England by Tuesday. The warm weather is attributed to the tail end of Tropical Storm Dexter, which is drawing warm air across the country from the southwest. Health officials caution about potential 'significant impacts' on health and social care services, as this could mark the fourth heatwave of the year. The Met Office confirms confidence in the initial temperature rise but notes uncertainty regarding the exact duration of the warm spell.
